Search

Search Constraints

You searched for: Author/Creator Lin, Huamao

Search Results

1. Brigatinib vs crizotinib in ALK TKI-naive ALK+ NSCLC: final results from ALTA-1L. (March 2022)

2. Mobocertinib (TAK-788) in epidermal growth factor receptor gene (EGFR) exon 20 insertion mutation-positive (EGFRex20ins+) metastatic non-small cell lung cancer (mNSCLC): results from the platinum-pretreated patients (PPP) cohort of a phase 1/2 study. (March 2022)

3. Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study. (April 2023)